Physician profile
Yuri Boyechko
NPI 1306253679
$2,648.56
in general payments reported to CMS, 2019-2025
29 companies · $2,039 in 2025
The $2,039 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $310 · 2021: $13.71 · 2022: $16.99 · 2023: $15.87 · 2024: $37.07 · 2025: $2,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $724.08 | 2025 | Rapiblyk |
| Novartis Pharmaceuticals Corporation | $277.81 | 2024-2025 | |
| Astellas Pharma US INC | $198.00 | 2019 | |
| Philips North America LLC | $192.70 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Heartflow, INC. | $129.45 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.34 | 2020-2025 | Lifevest |
| Boston Scientific Corporation | $100.07 | 2020-2025 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $88.72 | 2020 | |
| Janssen Pharmaceuticals, INC | $84.52 | 2020-2024 | Xarelto |
| Amgen INC. | $76.14 | 2020-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $73.37 | 2025 | Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $57.24 | 2025 | |
| Novo Nordisk INC | $56.37 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $46.29 | 2019-2021 | |
| Medtronic Vascular, INC. | $42.12 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.61 | 2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $40.03 | 2025 | Optimizer |
| Abbott Laboratories | $35.25 | 2022-2025 | Mitraclip |
| Pfizer INC. | $34.79 | 2025 | |
| Edwards Lifesciences Corporation | $34.22 | 2025 | Sapien 3 Ultra Resilia |
| Alnylam Pharmaceuticals INC. | $31.63 | 2025 | Onpattro |
| Bridgebio Pharma, INC. | $28.89 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $22.99 | 2025 | Inspire |
| Abiomed | $20.83 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.63 | 2020 | |
| Lilly USA, LLC | $18.00 | 2025 | Zepbound |
| Azurity Pharmaceuticals, INC. | $17.88 | 2025 | Edarbyclor |
| Kestra Medical Technology Services, INC. | $17.58 | 2025 | Assure Wcd |
| Atricure, INC. | $15.01 | 2025 | Atriclip Laa Exclusion System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuri Boyechko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.